Although AI, machine learning, and quantum computing will someday improve our ability to forecast the future, for now Life Science Leader continues to seek knowledge from a cross section of life sciences industry execs.
Outsourced Pharma Chief Editor Louis Garguilo talks with two biotech CEOs about why they believe this industry should expect an infusion of technology and improved productivity in the coming years.
With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.
Therapy designations and FDA approvals don’t mean much if the product can’t be manufactured at the level necessary to meet market demand. Here, a cross section of biopharma manufacturing executives offer their opinions on what to expect in biopharma manufacturing for 2020 and beyond.
Here are the critical action items cell and gene therapy professionals should heed to keep pace with the sector’s ever-evolving regulations.
Though the U.S. hasn’t witnessed a biosimilar market explosion as many anticipated, uptake has slowly but surely been creeping upward. I’m far from alone in believing it’s too early to propose dismantling the biosimilar industry.
Virtual trials have been around for years, so why are they still met with skepticism? Clinical trial executives from Janssen and Astellas weigh in on this hot topic for 2020.
As politics, finance and biopharma seem forever intertwined, we sought the counsel of five biopharmaceutical industry financial experts toward helping you prepare for what to expect in 2020 – and beyond.
We asked John Oyler, an American entrepreneur and the chairman, cofounder, and CEO of BeiGene, why he decided to build a global biopharmaceutical company with roots beginning in China. His answer may surprise you.
Tim Ring, former chairman and CEO of C.R. Bard, shares how he and his spouse retired to build TEAMFund, a $30 million impact investment fund focused on having a positive impact on health in some of the most resource constrained areas of the world.
In this first of a series of articles dedicated to the Women in Bio Boardroom Ready program, we discuss what the program entails and feedback from some previous participants.
Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at nearly $2 billion, in just seven years.
Laura Indolfi and Elizabeth O’Day discuss how being chosen for the Massachusetts Next Generation Initiative (MassNextGen) changed their respective biopharma companies.
Catherine Clark, a professor and Duke University and impact investment expert, provides a comprehensive overview of impact investing, a growing trend sure to catch on in life sciences.
Six biopharma CEOs talk tariff wars, politics, and other concerns for 2020 and beyond.
Five biopharmaceutical industry finance experts share their perspectives for what the industry can expect in 2020 and beyond.
Seven biopharmaceutical executives share their perspectives on what to expect in biopharma manufacturing in 2020 and beyond.
Chief editor Rob Wright explains what differentiates the CNS Summit from other biopharmaceutical industry conferences.
The little known story of an immigrant couple making a $15 million difference for U.S. veterans.